by JAMA Network
Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
Language
🇺🇲
Publishing Since
2/12/2015
Email Addresses
1 available
Phone Numbers
0 available
March 20, 2025
<p>Interview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD.<br /> <br /> <strong>Related Content:</strong></p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.0236?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions</a></li> <li><a class="related-article" href= "https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.0130?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer</a></li> </ul>
February 27, 2025
<p>Interview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD.<br /> <br /> <strong>Related Content:</strong></p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.7033?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality</a></li> </ul>
January 30, 2025
<p>Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD.<br /> <br /> <strong>Related Content:</strong></p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.6168?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy</a></li> </ul>
JAMA Network
NEJM Group
JAMA Network
Vinay Prasad, MD MPH
Sam and Karine
American Society of Clinical Oncology (ASCO)
JAMA Network
American Society of Clinical Oncology (ASCO)
Hidden Brain, Shankar Vedantam
Marketplace
Springer Nature Limited
Science Magazine
Mayo Clinic
The Curious Clinicians
Freakonomics Radio + Stitcher
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.